AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- Myeloid Leukemia
- First Posted Date
- 2007-07-09
- Last Posted Date
- 2010-12-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT00497991
- Locations
- 🇳🇱
Research Site, Rotterdam, Netherlands
Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD
- Interventions
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2012-11-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 660
- Registration Number
- NCT00496470
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Phase I Study in Patients With Solid Tumours
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2010-09-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 148
- Registration Number
- NCT00496028
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
Phase 1
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2014-03-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 172
- Registration Number
- NCT00494221
- Locations
- 🇯🇵
Research Site, Saitama, Japan
Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT00494234
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer
Phase 2
Completed
- Conditions
- Ovarian Neoplasm
- Interventions
- Drug: KU-0059436 (AZD2281)(PARP inhibitor)
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 58
- Registration Number
- NCT00494442
- Locations
- 🇸🇪
Research Site, Lund, Sweden
AZD6765 for Treatment Resistant Depression
Phase 2
Completed
- Conditions
- Depression
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 34
- Registration Number
- NCT00491686
- Locations
- 🇺🇸
Research Site, Rockville, Maryland, United States
Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2012-08-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 137
- Registration Number
- NCT00489853
- Locations
- 🇨🇭
Research Site, Basel, Basel Stadt, Switzerland
Interaction Between ABT-335, Rosuvastatin and Warfarin
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT00487136
- Locations
- 🇺🇸
Site Ref # / Investigator 5290, Little Rock, Arkansas, United States
FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis
Phase 3
Terminated
- Conditions
- Psychotic DisordersSchizophreniaBipolar Disorder
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00486798
- Locations
- 🇸🇪
Research Site, Vaxjo, Sweden
© Copyright 2025. All Rights Reserved by MedPath